The clinical role of dual energy X-ray absorptiometry

European Journal of Radiology

Volumn 71, Issue 3, 2009, Pages 406-414

  Blake, Glen M ^a   Fogelman, Ignac ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Bone mineral density; Dual energy X ray absorptiometry; Fracture risk; Osteoporosis; Treatment

Indexed keywords

BONE MINERAL DENSITY; DUAL ENERGY X-RAY ABSORPTIOMETRY; FRACTURE RISK; OSTEOPOROSIS; TREATMENT;

BONE; FRACTURE; LIGHT ABSORPTION; MINERALS; SILICATE MINERALS;

HEALTH RISKS;

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITOMETRY; BONE DENSITY; CLINICAL FEATURE; CONSENSUS; DIAGNOSTIC ACCURACY; DUAL ENERGY X RAY ABSORPTIOMETRY; FRAGILITY FRACTURE; HIP; HUMAN; OSTEOPOROSIS; PRIORITY JOURNAL; RISK; SPINE; TREATMENT RESPONSE; WORLD HEALTH ORGANIZATION;

ABSORPTIOMETRY, PHOTON; BONE DENSITY; DENSITOMETRY; FRACTURES, BONE; HUMANS; IMAGE ENHANCEMENT; OSTEOPOROSIS;

EID: 69849101242     PISSN: 0720048X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejrad.2008.04.062     Document Type: Article

References (80)

1. Cummings S.R., and Melton L.J. Epidemiology and outcomes of osteoporotic fractures. Lancet 359 (2002) 1761-1767
2. Johnell O., and Kanis J.A. An estimate of the worldwide prevelance and disability associated with osteoporotic fractures. Osteoporos Int 17 (2006) 1726-1733
3. Kanis J.A., Black D., Cooper C., et al. A new approach to the development of assessment guidelines for osteoporosis. Osteoporos Int 13 (2002) 527-536
4. Dolan P., and Torgerson D.J. The cost of treating osteoporotic fractures in the United Kingdom female population. Osteoporos Int 8 (1998) 611-617
5. Melton L.J., Gabriel S.E., Crowson C.S., Tostesen A.N.A., Johnell O., and Kanis J.A. Cost-equivalence of different osteoporotic fractures. Osteoporos Int 14 (2003) 383-388
6. Centre J.R., Nguyen T.V., Schneider D., Sambrook P.N., and Eisman J.A. Mortality after all major types of osteoporotic fractures in men and women: an observational study. Lancet 353 (1999) 878-882
7. Sambrook P., and Cooper C. Osteoporosis. Lancet 367 (2006) 2010-2018
8. Clark S. Osteoporosis - the disease of the 21st century?. Lancet 359 (2002) 1714
9. Genant H.K., Engelke K., Fuerst T., et al. Noninvasive assessment of bone mineral and structure: state of the art. J Bone Miner Res 11 (1996) 707-730
10. Storm T., Thamsborg G., Steiniche T., Genant H.K., and Sorensen O.H. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322 (1990) 1265-1271
11. WHO. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: technical report series 843. WHO, Geneva, 1994.
12. Kanis J.A., and Gluer C.-C. An update on the diagnosis and assessment of osteoporosis with densitometry. Osteoporos Int 11 (2000) 192-202
13. Black D.M., Cummings S.R., Karpf D.B., et al. Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348 (1996) 1535-1541
14. Cummings S.R., Black D.M., Thompson D.E., et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 280 (1998) 2077-2082
15. Harris S.T., Watts N.B., Genant H.K., et al. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. JAMA 282 (1999) 1344-1352
16. McClung M.R., Geusens P., Miller P.D., et al. Effect of risedronate treatment on hip fracture risk in elderly women. N Engl J Med 344 (2001) 333-340
17. Chesnut C.H., Skag A., Christiansen C., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19 (2004) 1241-1249
18. Black D.M., Delmas P.D., Eastell R., et al. Once-yearly zolendronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356 (2007) 1809-1822
19. Lyles K.W., Colon-Emeric C.S., Magaziner J.S., et al. Zolendronic acid and clinical fractures and mortality after hip fracture. N Engl J Med 357 (2007) 1799-1809
20. Ettinger B., Black D.M., Mitlak B.H., et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. JAMA 282 (1999) 637-645
21. Neer R.M., Arnaud C.D., Zanchetta J.R., et al. Effect of recombinant human parathyroid hormone (1-34) fragment on spine and non-spine fractures and bone mineral density in postmenopausal osteoporosis. N Engl J Med 344 (2001) 1434-1441
22. Greenspan S.L., Bone H.G., Ettinger M.P., et al. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis. Ann Intern Med 146 (2007) 326-339
23. Meunier P.J., Roux C., Seeman E., et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350 (2004) 459-468
24. Reginster J.Y., Seeman E., De Vernejoul M.C., et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 90 (2005) 2816-2822
25. Seeman E., Vellas B., Benhamou C., et al. Strontium ranelate reduces the risk of vertebral and nonvertebral fractures in women eighty years of age and older. J Bone Miner Res 21 (2006) 1113-1120
26. Kanis J.A., Delmas P., Burckhardt P., Cooper C., and Torgerson D. Guidelines for diagnosis and treatment of osteoporosis. Osteoporos Int 7 (1997) 390-406
27. Genant H.K., Cooper C., Poor G., et al. Interim report and recommendations of the World Health Organization task-force for osteoporosis. Osteoporos Int 10 (1999) 259-264
28. National Osteoporosis Foundation (NOF). Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int 1998;8(suppl. 4):S7-80.
29. International Society of Clinical Densitometry (ISCD). Official positions of the International Society for Clinical Densitometry: updated 2005. Available online at www.iscd.org/visitors/positions/official.cfm.
30. Marshall D., Johnell O., and Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 312 (1996) 1254-1259
31. Stone K.L., Seeley D.G., Lui L.-Y., et al. BMD at multiple sites and risk of fracture of multiple types: long-term results from the Study of Osteoporotic Fractures. J Bone Miner Res 18 (2003) 1947-1954
32. Johnell O., Kanis J.A., Oden A., et al. Predictive value of BMD for hip and other fractures. J Bone Miner Res 20 (2005) 1185-1194
33. Eastell R. Treatment of postmenopausal osteoporosis. N Engl J Med 338 (1998) 736-746
34. Gluer C.-C. Monitoring skeletal change by radiological techniques. J Bone Miner Res 14 (1999) 1952-1962
35. Fogeman I., and Blake G.M. Different approaches to bone densitometry. J Nucl Med 41 (2000) 2015-2025
36. Guglielmi G., and Lang T.F. Quantitative computed tomography. Semin Musculoskelet Radiol 6 (2002) 219-227
37. Blake G.M., and Fogelman I. Clinical use of instruments that measure peripheral bone mass. Curr Opin Endocrinol Diab 9 (2002) 502-511
38. Stewart A., and Reid D.M. Quantitative ultrasound in osteoporosis. Semin Musculoskelet Radiol 6 (2002) 229-232
39. Lu Y., Genant H.K., Shepherd J., et al. Classification of osteoporosis based on bone mineral densities. J Bone Miner Res 16 (2001) 901-910
40. Faulkner K.G., Von Stetton E., and Miller P. Discordance in patient classification using T-scores. J Clin Densitom 2 (1999) 343-350
41. Blake G.M., and Fogelman I. Peripheral or central densitometry: does it matter which technique we use?. J Clin Densitom 4 (2001) 83-96
42. Looker A.C., Wahner H.W., Dunn W.L., et al. Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int 8 (1998) 468-489
43. Cummings S.R., Black D.M., Nevitt M.C., et al. Bone density at various sites for prediction of hip fractures. Lancet 341 (1993) 72-75
44. Black D.M., Palermo L., and Bauer D. How well does bone mass predict long-term risk of hip fracture?. Osteoporos Int 11 suppl. 2 (2000) S59
45. Barr R.J., Adebajo A., Fraser W.D., et al. Can peripheral DXA measurements be used to predict fractures in elderly women living in the community?. Osteoporos Int 16 (2005) 1177-1183
46. Faulkner K.G., Roberts L.A., and McClung M.R. Discrepancies in normative data between Lunar and Hologic DXA systems. Osteoporos Int 6 (1996) 432-436
47. Hanson J. Standardization of femur BMD. J Bone Miner Res 12 (1997) 1316-1317
48. Blake G.M., Chinn D.J., Steel S.A., et al. A list of device specific thresholds for the clinical interpretation of peripheral x-ray absorptiometry examinations. Osteoporos Int 16 (2005) 2149-2156
49. Kanis J.A. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 359 (2002) 1929-1936
50. Kanis J.A., Borgstrom F., De Laet C., et al. Assessment of fracture risk. Osteoporos Int 16 (2005) 581-589
51. De Laet C., Oden A., Johansson H., Johnell O., Jonsson B., and Kanis J.A. The impact of the use of multiple risk factors for fracture on case-finding strategies: a mathematical approach. Osteoporos Int 16 (2005) 313-318
52. Kanis J.A., Johnell O., Oden A., Dawson A., De Laet C., and Jonsson B. Ten-year probabilities of osteoporotic fractures according to BMD and diagnostic thresholds. Osteoporos Int 12 (2001) 989-995
53. Kanis J.A., Oden A., Johnell O., et al. The use of clnical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int 18 (2007) 1033-1046
54. Kanis J.A., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 35 (2004) 375-382
55. Kanis J.A., Johansson H., Oden A., et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res 19 (2004) 893-899
56. Kanis J.A., Johansson H., Oden A., et al. A family history of fracture and fracture risk: a meta-analysis. Bone 35 (2004) 1029-1037
57. Kanis J.A., Johnell O., Oden A., et al. Smoking and fracture risk: a meta-analysis. Osteoporos Int 16 (2005) 155-162
58. Kanis J.A., Johansson H., Johnell O., et al. Alcohol intake as a risk factor for fracture. Osteoporos Int 16 (2005) 737-742
59. De Laet C., Kanis J.A., Oden A., et al. Body mass index as a predictor of fracture risk: a meta-analysis. Osteoporos Int 16 (2005) 1330-1338
60. Kanis J.A., Johnell O., Oden A., et al. The use of multiple sites for the diagnosis of osteoporosis. Osteoporos Int 17 (2006) 527-534
61. Blake G.M., Patel R., Knapp K.M., and Fogelman I. Does the combination of two BMD measurements improve fracture discrimination?. J Bone Miner Res 18 (2003) 1955-1963
62. Johansson H., Oden A., Johnell O., et al. Optimisation of BMD measurements to identify high risk groups for treatment - a test analysis. J Bone Miner Res 19 (2004) 906-913
63. Kanis J.A., Oden A., Johnell O., Jonsson B., De Laet C., and Dawson A. The burden of osteoporotic fractures: a method of setting intervention thresholds. Osteoporos Int 12 (2001) 417-427
64. Borgstrom F., Johnell O., Kanis J.A., et al. At what hip fracture risk is it cost effective to treat? International intervention thresholds for the treatment of osteoporosis. Osteoporos Int 17 (2006) 1459-1471
65. Kanis J.A., Borgstrom F., Zethraeus N., Johnell O., Oden A., and Jonsson B. Intervention thresholds for osteoporosis in the UK. Bone 36 (2005) 22-32
66. Kanis J.A., Borgstrom F., Johnell O., Oden A., Sykes D., and Jonsson B. Cost-effectiveness of raloxifene in the UK: an economic evaluation based on the MORE study. Osteoporos Int 16 (2005) 15-25
67. Borgstrom F., Carisson A., Sintonen H., et al. Cost-effectiveness of risedronate in the treatment of osteoporosis: an international perspective. Osteoporos Int 17 (2006) 996-1007
68. Borgstrom F., Jonsson B., Strom O., and Kanis J.A. An economic evaluation of strontium ranelate in the treatment of osteoporosis in a Swedish setting based on the results of the SOTI and TROPOS trials. Osteoporos Int 17 (2006) 1781-1793
69. Zethraeus N., Borgstrom F., Strom O., and Kanis J.A. Cost-effectiveness of the treatment and prevention of osteoporosis - a review of the literature and a reference model. Osteoporos Int 18 (2007) 9-23
70. Van Staa T.P., Kanis J.A., Geusens P., Boonen A., Leufkens H.G., and Cooper C. The cost-effectiveness of bisphosphonates in postmenopausal women based on individual long-term fracture risks. Value Health 10 (2007) 348-357
71. Bonnick S.L., Johnston Jr. C.C., Kleerekoper M., Lindsay R., Miller P., Sherwood L., et al. Importance of precision in bone density measurements. J Clin Densitom 4 (2001) 105-110
72. Svendsen O.L., Hassager C., Skodt V., and Christiansen C. Impact of soft tissue on in vivo accuracy of bone mineral measurements in the spine, hip and forearm: a human cadaver study. J Bone Miner Res 10 (1995) 868-873
73. Patel R., Blake G.M., Rymer J., and Fogelman I. Long-term precision of DXA scanning assessed over seven years in forty postmenopausal women. Osteoporos Int 11 (2000) 68-75
74. Kiebzak G.M., Faulkner K.G., Wacker W., Hamdy R., Seier E., and Watts N.B. Effect of precision error on T-scores and diagnostic classification of bone status. J Clin Densitom 10 (2007) 239-243
75. Lee D.C., Wren T.A.L., and Gilanz V. Correcting DXA pediatric bone mineral density measurements to account for fat inhomogeneity. J Bone Miner Res 22 suppl. 1 (2007) S494-S495
76. Griffith J.F., Yeung D.K.W., Antonio G.E., Wong S.Y.S., Kwok T.C.K., Woo J., et al. Vertebral marrow fat content and diffusion and perfusion indexes in women with varying bone density: MR evaluation. Radiology 241 (2006) 831-838
77. Blake G.M., and Fogelman I. How important are BMD accuracy errors for the clinical interpretation of DXA scans?. J Bone Miner Res 23 (2008) 457-462
78. Tothill P., and Hannan J. Precision and accuracy errors of measuring changes in bone mineral density by dual-energy X-ray absorptiometry. Osteoporos Int 18 (2007) 1515-1523
79. Faulkner K.G. Bone densitometry: choosing the proper site to measure. J Clin Densitom 1 (1998) 279-285
80. Blake G.M., Herd R.J.M., and Fogelman I. A longitudinal study of supine lateral DXA of the lumbar spine: a comparison with posteroanterior spine, hip and total body DXA. Osteoporos Int 16 (1996) 462-470